Pharmaceuticals Australia

Australia CAR-T Cell Therapy Market Analysis, 2024–2034

Australia CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $59.7 Mn Estimated value
Estimate 2025 $74.9 Mn 1.2% of the global market
Projected 2034 $582.9 Mn 677.9% Adds $507.9 Mn over 9 forecast years
CAGR 2025–2034 25.6% Faster than 92% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.16% of the global market.
  • In APAC, the largest is China at $539.6 Mn.
  • Fastest growing: India at 27.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$507.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
CAR-T Cell Therapy Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $59.7 Mn — —
2025 (base) $74.9 Mn +$15.3 Mn —
2026 (forecast) $94.1 Mn +$19.2 Mn +25.6%
2027 (forecast) $118.2 Mn +$24.1 Mn +57.8%
2028 (forecast) $148.5 Mn +$30.3 Mn +98.1%
2029 (forecast) $186.5 Mn +$38.0 Mn +148.9%
2030 (forecast) $234.2 Mn +$47.7 Mn +212.6%
2031 (forecast) $294.2 Mn +$60.0 Mn +292.6%
2032 (forecast) $369.5 Mn +$75.3 Mn +393.1%
2033 (forecast) $464.1 Mn +$94.6 Mn +519.3%
2034 (forecast) $582.9 Mn +$118.8 Mn +677.9%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $6.46 Bn
  2. North America $3.01 Bn
  3. US $2.51 Bn
  4. APAC $1.19 Bn
  5. Europe $1.10 Bn
  6. China $539.6 Mn
  7. Canada $445.6 Mn
  8. Japan $420.2 Mn
  9. Latin America $313.2 Mn
  10. Germany $244.3 Mn
  11. Middle East $227.1 Mn
  12. France $188.8 Mn
  13. UK $181.1 Mn
  14. Brazil $176.7 Mn
  15. Italy $161.3 Mn
  16. India $138.3 Mn
  17. Saudi Arabia $127.4 Mn
  18. Ecuador $117.0 Mn
  19. Spain $110.6 Mn
  20. Mexico $109.0 Mn
  21. Africa $98.4 Mn
  22. Russia $76.4 Mn
  23. Australia (this report) $74.9 Mn
  24. New Zealand $68.7 Mn
  25. South Africa $37.6 Mn
  26. UAE $27.9 Mn
  27. Egypt $17.1 Mn
  28. Philippines $14.1 Mn
  29. Hong Kong $10.9 Mn
  30. Malaysia $9.7 Mn
  31. Singapore $7.0 Mn
  32. Thailand $6.9 Mn
  33. Kenya $4.5 Mn

The Australia CAR-T Cell Therapy Market Analysis Executive Summary

CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.

Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).

Australia CAR-T Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for CAR-T Cell Therapy Market in Australia

The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in Australia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.

Clinical trials

50 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Chongqing Precision Biotech Co., Ltd 25 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Bristol-Myers Squibb 13 active trials on ClinicalTrials.gov (opens in a new tab)
  3. AstraZeneca 12 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Novartis AG 11 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Hebei Senlang Biotechnology Inc., Ltd. 9 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 7,618 papers since 2021 (worldwide)

  1. Ligand/receptor-based chimeric antigen receptors: a promising alternative to conventional scFv designs in cancer immunotherapy. Transplantation and cellular therapy, 2026
  2. Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management. Seminars in neurology, 2026
  3. LILRB1 as a novel therapeutic target for CAR-T therapy in diffuse large B cell lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy, 2026
  4. Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones. PloS one, 2026
  5. Cell-based Therapies in Acute Lymphoblastic Leukemia Treatment: Current Advancements and Limitations. Clinical and experimental medicine, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

CAR-T Cell Therapy in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on CAR-T Cell Therapy are running in Australia?
50 studies are recruiting, active or about to start in Australia.[4]
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about CAR-T Cell Therapy in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on cell and gene therapy and oncology

See the topic